Description

Sitagliptin Phosphate Description

Product name: Sitagliptin phosphate tablets (Janovi)
Packaging specifications: Domestic version 100mg7 tablets4 plates ? Product dosage form: tablets ? Packaging unit: box
Approval number: National Medicine Standard H20237004  Drug standard code: 86904495000388
Manufacturer: Hangzhou Merck Pharmaceutical Co., Ltd.
Product barcode: 6951283550895

Sitagliptin, widely known as Januvia®, is a DPP 4 inhibitor used in managing type 2 diabetes by enhancing incretin hormone levels to improve insulin secretion and reduce glucagon levels.
Jianovi is the domestic version produced by Hangzhou MSD Pharmaceutical, approved under NMPA number H20237004, with product code 86904495000388 and barcode 6951283550895.

In post-market monitoring, common reported side effects include headache, upper respiratory infection, pancreatitis, hypersensitivity, renal impairment, and joint pain—similar to other sitagliptin formulations.

 Technical Specifications

 Mechanism of Action & Clinical Profile

1. DPP 4 inhibition: Sitagliptin increases GLP-1 and GIP, boosting insulin and lowering glucagon in response to meals.

2. Low hypoglycemia risk: As glycemic control normalizes, risk of hypoglycemia is low.

3. Pharmacokinetics: Oral bioavailability ~87%, half-life 8–14h, predominantly renal excretion (~80%)en.wikipedia.org+1zh.wikipedia.org+1.

4. Safety considerations: Monitor renal function in compromised patients; rare reports of pancreatitis and serious hypersensitivity.

 Why Buy Jianovi Sitagliptin?

• Market-approved by NMPA (H20237004), from a joint venture of Merck

• GMP quality pharmaceutical product, pre-packaged as tablets

• Research-grade reliability, ideal for pharmacological and PK/PD labs

•  Full product traceability via barcode and drug code

 Related Research Materials

• Sitagliptin Phosphate Tablets 50mg (Generic)

• Sitagliptin + Metformin Combo Tablets

• Empagliflozin & Canagliflozin SGLT-2 Inhibitor Tablets

 Final Summary

Jianovi Sitagliptin Phosphate Tablets 100mg deliver a pharma-grade DPP 4 inhibitor option for diabetes research. With proven safety data, Merck-backed authenticity, and full traceability, it provides reliability for metabolic, pharmacokinetic, and endocrinology studies.
Strictly for laboratory research or analytical purposes only.